NMT Medical Inc.

Frank Martin was appointed President and Chief Executive Officer of NMT Medical on February 9, 2009. Martin was elected to NMT’s Board of Directors in February 2001. Since March 2007, Martin has been the Chief Executive Officer of Corindus Inc., a company that designs and manufactures robotic systems for interventional cardiology. Prior to that position, he was Executive Chairman of Cappella Inc., a developer and manufacturer of coronary stents. From 2000 to 2005, he was the Chairman and Chief Executive Officer of Florence Medical LTD. From 1993 to 2000, he was founder, Chairman and Chief Executive Officer of CorMedica Corporation. Prior to that, Martin was with Becton Dickinson & Co. and Abbott Laboratories, where he held senior management positions, domestically and internationally, in marketing, sales and business development. Martin is a board member of two privately held medical device companies.

Richard E. Davis is currently Chief Operating Officer of NMT Medical, Inc.. He has served as the Company’s Executive Vice President, Chief Financial Officer and Corporate Secretary since February 2001. From August 2000 to February 2001, Mr. Davis served as the Company’s Interim Chief Financial Officer through his employment with the consulting firm of Argus Management Corporation. From July 1998 to July 2000, Mr. Davis was Vice President and Chief Financial Officer of Q-Peak, Inc., a marketer and manufacturer of solid-state laser systems. Prior to July 1998, Mr. Davis was employed for ten years by TJX Companies, Inc., a worldwide off-price retailer of apparel and home fashions, in various senior financial management positions where he was responsible for business and strategic planning, cash flow and expense management and accounting and operational controls.

Array

David L. West, Ph.D., MPH, was elected a director of the Company’s board in July 2007. Dr. West is a leading expert in medical device laws and regulation, medical device development and evaluation, regulatory strategy and policy formulation, and device/drug/biologic combination products. Dr. West has more than 26 years of experience in the U.S. Public Health Service, including over ten years of management with the U.S. Food and Drug Administration (FDA). He currently is Vice President, Medical Device Development with Quintiles Consulting of Rockville, MD.

James E. Lock, M.D. , age 57, was elected a director of the Company in August 2000. Since March 2002, Dr. Lock has been Physician-in-Chief at Children s Hospital Boston, and since October 1993, he has been Chairman of the Department of Cardiology at Children s Hospital Boston and the Alexander S. Nadas Professor of Pediatrics at Harvard Medical School. Dr. Lock attended medical school at Stanford University and pursued his pediatric residency and cardiology fellowship at the University of Minnesota. Thereafter, he trained in cardiovascular physiology for two years at the University of Toronto, Hospital for Sick Children. In September 1999, a device invented by Dr. Lock and licensed to the Company became the first septal occlusion device to receive United States Food and Drug Administration approvals under the Humanitarian Device Exemption regulations for use inside the human heart in the United States. During his career, Dr. Lock has trained numerous academic physicians in cardiopulmonary physiology, experimental interventional cardiology, and clinical interventional cardiology. The earliest trainees are now becoming directors of pediatric cardiology divisions, cardiac catheterization laboratories, and intensive care units. Dr. Lock is an inventor on seven U.S. patents and serves as a trustee of Children s Hospital Boston and the Children s Hospital Trust Board. He is also the president of the Boston Children s Heart Foundation and is the president of the Friends of the Aldo Castaneda Foundation.